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osting by EAbstract Percutaneous mitral balloon valvuloplasty (MBV) was introduced in 1984 by Inoue who
developed the procedure as a logical extension of surgical closed commissurotomy. Since then, MBV
has emerged as the treatment of choice for severe pliable rheumatic mitral stenosis (MS). With
increasing experience and better selection of patient, the immediate results of the procedure have
improved and the rate of complications declined. When the reported complications of MBV are
viewed in aggregate, complications occur at approximately the following rates: mortality (0–
0.5%), cerebral accident (1–2%), mitral regurgitation (MR) requiring surgery (1.6–3%). These
complication rates compare favorably to those reported after surgical commissurotomy. Several ran-
domized trials reported similar hemodynamic results with MBV and surgical commissurotomy.
Restenosis after MBV ranges from 4% to 70% depending on the patient selection, valve morphol-
ogy, and duration of follow-up. Restenosis was encountered in 31% of the author’s series at mean
follow-up 9 ± 5.2 years (range 1.5–19 years) and the 10, 15, and 19 years restenosis-free survival
rates were (78 ± 2%) (52 ± 3%) and (26 ± 4%), respectively, and were signiﬁcantly higher for
patients with favorable mitral morphology (MES 6 8) at 88 ± 2%, 67 ± 4% and 40 ± 6%), respec-
tively (P< 0.0001). The 10, 15, and 19 years event-free survival rates were (88 ± 2%, 60 ± 4% and
28 ± 7%, respectively, and were signiﬁcantly higher for patients with favorable mitral morphology
(92 ± 2%, 70 ± 4% and 42 ± 7%, respectively (P< 0.0001). The effect ofMBV on severe pulmon-
ary hypertension, concomitant severe tricuspid regurgitation, left ventricular function, left atrial size,
and atrial ﬁbrillation are addressed in this review. In addition, the application of MBV in speciﬁc
clinical situations such as in children, during pregnancy and for restenosis is discussed.
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failure and is ﬁnally fatal unless mechanical intervention en-
larges the mitral valve oriﬁce to permit adequate cardiac out-
put at a tolerable left atrial pressure. Starting over 50 years
ago a variety of surgical techniques were developed; ﬁrst
closed commissurotomy followed by open commissurotomy
after the introduction of the cardiopulmonary bypass (Har-
ken et al., 1949; John et al., 1983). Mitral balloon valvulo-
plasty was introduced in 1984 by the Japanese surgeon
Inoue, who developed the procedure as a logical extension
of surgical closed commissurotomy (Inoue et al., 1984). Since
then, balloon valvuloplasty has emerged as the treatment of
choice for severe pliable rheumatic mitral stenosis. The mech-
anism by which both procedures reduce stenosis is the same
and involves mechanical dilatation of fused commissures
(McKay et al., 1987). Several randomized trials reported
similar hemodynamic results with balloon valvuloplasty and
surgical commissurotomy. However, periprocedural compli-
cations in surgical patients were somewhat higher (Patel
et al., 1991; Turi et al., 1991; Reyes et al., 1994; Arora
et al., 1993; Farhat et al., 1998). Both forms of commissur-
otomy eliminate the risks common to prosthetic valves,
which include primary valve failure, thromboembolism, and
endocarditis. The purpose of this review is to summarize
the immediate and long-term results up to 19 years of
MBV, its complications, and elucidate the effect of MBV
on severe pulmonary hypertension, concomitant severe tri-
cuspid regurgitation, left ventricular function, left atrial size,
and atrial ﬁbrillation. Also, the applications of MBV in
speciﬁc clinical situations as in children, during pregnancy,
and for restenosis following previous surgical or balloon
commissurotomy, are discussed.1.1. Techniques
The transseptal technique is the most common technique used
to perform MBV. The technique consists of advancing a cath-
eter over the wire across the interatrial septum after transseptal
puncture, enlarging the opening and advancing one large bal-
loon (Inoue balloon) or two smaller balloons (double-balloon
technique) across the mitral oriﬁce and inﬂating them within
the oriﬁce. Although acute and short-term outcomes differ lit-
tle between these two techniques (Abdullah et al., 1992; Park
et al., 1993), complications such as death, left ventricular per-
foration, and stroke appear to be less common with the Inoue
balloon. The multiple advantages of the Inoue balloon (Fawzy
et al., 1996), include low proﬁle of the device, the elimination
of the stiff guide wire (minimizing the risk of LV perforation),
easy maneuverability, and the stepwise dilation (gradual in-
crease of balloon size on sequential inﬂations).
1.2. Echocardiographic evaluation
Echocardiography is themainstay of the noninvasive evaluation
ofmitral stenosis. The transthoracic echocardiography provides
an evaluation of the valvular apparatus, mitral valve area
(MVA), left atria dimension, and associated valve lesions.
Doppler echo provides hemodynamic evaluation including
mean mitral gradient, MVA, assessment of concomitant tricus-
pid regurgitation (TR) and estimation of pulmonary artery pres-
sure. The morphologic evaluation of the mitral valve is
semiquantilated using echocardiographic score (echo score).
The scoring system evaluates leaﬂet thickening, mobility,
calciﬁcation, and subvalvular involvement on a scale of 0–4, as
described (Wilkins et al., 1988). The mitral valve morphology
is considered favorable if the mitral echocardiographic score
(MES) is68. Transesophageal (TEE) echo should be performed
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of systemic embolism or very obese patient where the left atrium
was not properly visualized.We do not recommend TEE as rou-
tine procedure before MBV (Fawzy et al., 2009).
1.3. Immediate hemodynamic results
The left atrial pressure, mean mitral gradient, and pulmonary
artery systolic pressure decreased signiﬁcantly after MBV with
corresponding increase in MVA. In the National Heart, Lung
Blood Institute Balloon Valvotomy Registry of 736 patients
(Reid et al., 1992), the MVA by echocardiographic assessment
was 1.09 ± 0.29 cm2 before the procedure and increased to
1.8 ± 0.15 cm2 after the procedure. In the author’s series,
547 consecutive patients (Fawzy et al., 2009) the echocardio-
graphic MVA was 0.92 ± 0.17 cm2 before the procedure,
and increased to 1.95 ± 0.29 cm2 after the procedure. A signif-
icant inverse relationship was found between the echo score
and post-procedure MVA where mitral valve morphology
was found to be a strong predictor of post-procedure mitral
opening (Wilkins et al., 1988; Fawzy et al., 2007). However,
good results could also be obtained in cases with relatively
high echo score.
1.4. Complications of balloon mitral valvuloplasty
In general, MBV is a safe procedure with high success rate,
particularly if the patients chosen have optimal valve morphol-
ogy as determined by echo score. When the reported rates of
complications of MBV are viewed in aggregate, complications
appear to occur at approximately the following rates: mortal-
ity (0–0.5%), cerebrovascular accident (CVA) (0.5–2%), car-
diac tamponade (0.7–1%), mitral regurgitation requiringFigure 1 Freedom from restenosis by Kaplan–Meier estimates for al
represent patients alive and uncensored at each year of follow-up.surgery (0.9–2%), mitral regurgitation of some degree (15%),
and atrial septal defect detected by dolor Doppler (20–23%)
which, however, closes or decreases in size in most patients
(Fawzy et al., 1996, in press; Ishikura et al., 1990).
2. Long-term follow-up and predictors of restenosis and
event-free survival
2.1. Mitral restenosis
The restenosis rate after MBV has been reported as 39% at
7 years (Hernandez et al., 1999) and was lower (31%) at
19 years in our younger population (mean age 31.5 ±
11 years) (Fawzy et al., 2007, 2009; Ben Farhat et al., 2001)
and was 20% in subgroup of patients with MES 6 8. The actu-
arial freedom from restenosis rates for this population were
78 ± 2% at 10 years, 52 ± 3% at 15 years, and 26 ± 5% at
19 years and were signiﬁcantly higher for patients with optimal
morphology (Fawzy et al., 2007) (echo score 68), namely
88 ± 2% at 10 years, 67 ± 4% at 15 years, 40 ± 6% at
19 years (Fig. 1). The predictors of being free from restenosis
were a low echo score (P< 0.0001) and post-procedure
MVAP 2.0 cm2 (Fawzy et al., 2007, 2009; Ben Farhat et al.,
2001; Iung et al., 1999).
2.2. Event-free survival
Iung et al. (1999) reported an event-free survival (survival with
freedom from redo MBV, MVR, cardiac death, NYHA func-
tional class III or IV) rate of 61% at 10 years in 528 patients
with successful PMBV (mean age, 49 years). Palacios et al.
(2002) (879 patients with successful MBV mean age, 55 years)
reported a rate of 38% at 12 years for patients with echo scorel patients and for patients with MES 6 8. Numbers at the bottom
Figure 3 Mean pulmonary artery systolic pressure estimated by
Doppler echocardiography for group A, B, C at baseline and at
follow-up over 12 months.
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vival rates at 10, 15, and 19 years were 88%, 60%, and 28%
respectively, in our relatively younger patients and were signif-
icantly higher for patients with MES 6 8 (92%, 70%, 42%,
respectively; P< 0.0001). The predictors of event-free survival
were low echo score and baseline A.F (P< 0.0001 and
P= 0.014, respectively) (Fig. 2) (Fawzy et al., 2007, 2009).
2.3. Regression of severe pulmonary hypertension
Pulmonary hypertension frequently complicates mitral steno-
sis and may signiﬁcantly inﬂuence the clinical ﬁndings and
prognosis of this condition. The increase in pulmonary arte-
rial pressure is often out of proportion to the degree of left
atrial hypertension, reﬂecting a major increase in pulmonary
vascular resistance (Wood, 1954; Walston et al., 1973;
Fawzy et al., 1996, 2004). To elucidate the effect of MBV
on severe pulmonary hypertension, the author (Fawzy
et al., 2004) studied 559 consecutive patients with severe
MS undergoing successful MBV. Patients were allocated to
three groups on the basis of their pulmonary artery stystolic
pressure (PASP) at cardiac catheterization prior to MBV;
group A (n= 345; 62%) had mild pulmonary hypertension
(PASP< 50 mmHg); group B (n= 183; 33%) had moderate
pulmonary hypertension (PASP 50–79 mmHg); and group C
(n= 31; 5%) had severe pulmonary hypertension (PASPP
80 mmHg). Immediately following valvuloplasty, the PASP
normalized in group A, in group B and C, pulmonary
hypertension decrease slightly with further substantial regres-
sion occurred overtime (Fig. 3) (Fawzy et al., 1996, 2004;
Dev and Shrivastava, 1991) and severe pulmonary hyperten-
sion normalized over 6–12 months in patients with successful
PMBV and follow-up MVAP 2.0 cm2 (Fawzy et al., 1996,
2004; Dev and Shrivastava, 1991).Figure 2 Kaplan–Meier event-free survival estimates (alive and free
patients with MES 6 8. Numbers at the bottom represent patients ali2.4. Regression of signiﬁcant tricuspid regurgitation
Signiﬁcant tricuspid valve regurgitation (TR) is a common
ﬁnding in patients with severe MS and in the majority of cases,
it is functional, resulting from right ventricular and tricuspid
annular dilation caused by long standing pulmonary hyperten-
sion. Although earlier reports suggested that TR can resolve
once the diseased mitral valve is replaced (Braunwald et al.,
1967; Pluth and Ellis, 1968), the results of later studies are con-
tradictory (Carpentier et al., 1974; Breyer et al., 1976). We and
other investigators demonstrated regression of signiﬁcant TR
after successful MBV in relatively young patients (mean ageof redo MBV, MVR, NYHA III or IV) for all patients and for
ve and uncensored at each year of follow-up.
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pulmonary hypertension (70 ± 22 mmHg) (Breyer et al.,
1976; Hannoush et al., 2004; Skudicky et al., 1994; Song
et al., 2003). On the other hand, Sagie et al. (1994) reported
no regression of TR in relatively older patients (mean age
57 ± 15 years) with severe MS and mild pulmonary hyperten-
sion (46 ± 15 mmHg). We demonstrated that severe pulmon-
ary hypertension is a strong predictor of regression of severe
TR after MBV (Hannoush et al., 2004).
2.5. Effect of mitral valvuloplasty on left ventricular function
In most cases of mitral stenosis, the left ventricular contractil-
ity is normal. However, in about one third of patients with mi-
tral stenosis left ventricular systolic function is reduced.
Preload reduction – caused by limited mitral inﬂow – and in-
creased afterload – precipitated by reﬂex vasoconstriction sec-
ondary to decreased cardiac output, act in concert to reduce
ejection performance (Gash et al., 1983; Fawzy et al., 1996).
We have demonstrated normalization of impaired LV systolic
function after successful MBV in patients with severe MS
(Fawzy et al., 1996).
2.6. Effect of MBV on left atrial size
Signiﬁcant reduction of LA size following successful mitral
Valvotomy was demonstrated by several investigators
(Takarada et al., 1992; Rittoo et al., 1993; Chen et al., 1992;
Stefadouros et al., 1999). To demonstrate the effect of MBV
on left atrial size, 205 consecutive patients (mean age
31 ± 11 years) were studied by the author (Stefadouros
et al., 1999). LA size at baseline and at mean follow-up of
31 ± 21 months after successful MBV (post-procedure
MVAP 1.5 cm2, MR 6 214) were analyzed. LA anteroposte-
rior dimension decreased in 87% of the patients (from
48.7 ± 7 mm to 42 ± 6.6 mm; P< 0.0001) whereas in 13%,
it remained unchanged or even increased. Similarly, LA vol-
ume was decreased in 93.5% of patients (from 92 ± 29 cm3
to 61 ± 24 cm3; P< 0.0001) whereas in the remaining 6.5%
of patients it remained unchanged or even increased. LA anter-
oposterior dimension returned to normal in 29.2% of patients
in sinus rhythm and in none for the patients with AF. Multiple
linear stepwise regression analysis was used to identify
predictors of regression of LA size after MBV. The variables
included in the analysis were gender, age, baseline anteropos-
terior LA dimension, baseline and post-procedure echo
MVA, echo score, and baseline A.F. Only two of these vari-
ables (baseline anteroposterior LA dimension and baseline
AF were shown to be predictors of regression of LA dimension
(P< 0.001) (Stefadouros et al., 1999).
2.7. Effect of MBV on the incidence of atrial ﬁbrillation
We demonstrated favorable effect of MBV on the long-term
incidence of chronic AF (8.9%) in patients with severe MS
(Fawzy et al., 2006) in comparison with the historical con-
trols (29%) of patients with severe MS and similar baseline
characteristics who were not submitted to intervention (Diker
et al., 1997). The predictors of AF were age, large
LA > 40 mm, small MVA (61.5 cm2) at follow-up (Fawzy
et al., 2006).3. Mitral balloon valvuloplasty in special circumstances
3.1. Mitral balloon valvuloplasty for restenosis after previous
surgical or balloon valvuloplasty
The outcome of MBV for mitral restenosis after surgical or
balloon commissurotomy has been addressed by several inves-
tigators (Medina et al., 1990; Serra et al., 1993; Jang et al.,
1995; Lau et al., 1996; Iung et al., 2000a,b; Fawzy et al.,
2005). In a series studied by the author comparing immediate
and long-term results of MBV in patients undergoing MBV as
initial procedure (524 patients) versus those undergoing re-
peated MBV for restenosis (56 patients) (Fawzy et al., 2005)
no death or technical failure were encountered in either group,
and mitral regurgitation >2/4 occurred in 2% of the patients
in both groups. Good immediate results (deﬁned as post-pro-
cedure MVAP 1.5 cm2 and MR< 2/4) were obtained in
93% of patients undergoing MBV for restenosis vs. 96% in
those with de novo MS (P= 0.4). Actuarial freedom from
restenosis rates at 10 years were 58% vs. 68% in de novo MS
(P= 0.18). Ten years event-free survival rates (survival with
freedom from MVR, reintervention, cardiac death, functional
class III or IV) were 54% vs. 80% for de novoMS. The predic-
tors of event-free survival were age, echo, score, and baseline
atrial ﬁbrillation (P= 0.002, P< 0.0001, P= 0.01, respec-
tively). We concluded that MBV is safe and provides good
immediate results in patients with restenosis. Long-term results
were inferior compared to de novo mitral stenosis but still sat-
isfactory, since more than half of the patients remained im-
proved at 10 years enabling the operation or reoperation to
be deferred (Fawzy et al., 2005).
3.2. Mitral balloon valvuloplasty during pregnancy
Pregnancy induces hemodynamic disturbances, mainly by
increasing the intravascular volume by 30–50% over nonpreg-
nant levels, the process commencing from the 6th week on-
wards and reaching a plateau towards the third trimester.
This hemodynamic burden, in conjunction with the physiolog-
ical increase of heart rate in pregnancy, results in an increase in
transmitral gradient and left atrial pressure which may lead to
acute pulmonary edema even in patients with moderate mitral
stenosis (Szekely et al., 1973; Elkayam and Bitar, 2005).
Although patients with cardiac disease are generally expected
to experience a symptomatic increase by one NYHA class dur-
ing pregnancy, this functional assessment may at times be
deceptive because some patients either over- or under-estimate
their symptoms, or limit their physical activity during preg-
nancy. However, when clinical assessment is complemented
by accurate echocardiographic evaluation, the pregnancy out-
come in such patients is usually predictable. Thus, without
intervention, the maternal mortality for patients with mitral
stenosis who are in NYHA classes I and II is 0.4% and signif-
icantly higher (6.8%) for those in NYHA classes III and IV,
particularly during labor and delivery (Szekely et al., 1973;
Hameed et al., 2001; Silversides et al., 2003). Although both,
surgical commissurotomy and mitral balloon valvuloplasty
have been shown to yield similarly favorable immediate and
long-term results, the maternal mortality associated with the
former procedure has been reported to be between 1.7% and
3.1%, as compared with no mortality with mitral balloon
130 M.E. FawzyValvuloplasty (Szekely et al., 1973; de Souza et al., 2001).
Moreover, surgical commissurotomy is associated with
signiﬁcantly higher fetal mortality ranging from 5% to 33%
(Elkayam and Bitar, 2005; de Souza et al., 2001) whereas only
one fetal death has so far been reported complicating mitral
balloon Valvuloplasty during pregnancy (Presbitero et al.,
1996). MBV should be avoided if possible during the ﬁrst tri-
mester and should be performed by experienced operators with
adequate abdominal and pelvic shielding with minimum
radiation exposure (De Andrade et al., 2001). Exposure can
be reduced by minimizing ﬂuoroscopy time by using echocar-
diography and Doppler, instead to obtain information on car-
diac function and degree of MR (Fawzy et al., 2001). The use
of the Inoue balloon catheter seems to be preferred over a dou-
ble-balloon technique, because it takes less time to perform
thus subjects the fetus to less radiation (Fawzy et al., 2001).
The author studied the immediate and long-term results of
MBV in 23 pregnant patients using the Inoue balloon tech-
nique (Fawzy et al., 2001). The procedure was successful in
all cases: the gradient fell from 15.7 ± 5.5 mmHg to
5 ± 1.6 mmHg and the MVA increased from 0.9 ± 0.2 cm2
to 2.0 ± 0.36 cm2. There were no maternal or fetal deaths
and all patients delivered at full term by vaginal delivery. At
follow-up (mean 5.1 ± 2.8 years range 1–9 years) of the 24 ba-
bies born alive (one pregnancy resulted in twins), one died sub-
sequently at one week of age from sudden infant death
syndrome and another died at 8 months of age from severe
pneumonia. All the remaining 22 children had normal growth
(Fawzy et al., 2001).
3.3. Mitral balloon valvuloplasty in children
MBV in children appears to be safe and effective similar to
adult patients (Fawzy et al., 2005). The author studied 30 chil-
dren and followed them up to 13 years. The Inoue balloon
technique was used in all. The procedure was successfulFigure 4 Freedom from restenosis by Kaplan–Meier estimates for gr
the bottom represent patients alive and uncensored at each year of fo(post-procedure MVAP 1.5 cm2, MR 6 2.4) in 28 patients
(93%). The mitral mean gradient decreased from 16 ±
4.5 mmHg to 6 ± 3 mmHg and the MVA increased from
0.8 ± 0.14 cm2 to 2.0 ± 0.3 cm2. No death or systemic embo-
lism was encountered, cardiac tamponade occurred in one pa-
tient and none of these patients develop severe MR. At long-
term follow-up, there was no signiﬁcant difference between
children and adult patients in the incidence of restenosis and
event-free survival (Fig. 4). The valve morphology rather tan
the patient age was the main determinant of valve restenosis
(Fawzy et al., 2005).
3.4. Comparison of mitral balloon valvuloplasty with surgical
commissurotomy
MBV is associated with less morbidity, shorter hospital stay,
avoidance of the discomfort and other problems associated
with thoracotomy, while the cost of surgery is at least twice
that of balloon Valvotomy in the United States (Arora et al.,
1993). The immediate results appear to be very similar to
closed and open surgical commissurotomy (Patel et al., 1991;
Turi et al., 1991; Reyes et al., 1994; Arora et al., 1993; Farhat
et al., 1998) while operative mortality from closed commissur-
otomy was 2.97% (Commerford et al., 1982) was higher than
that reported after PMBV (0.05%) Fawzy et al., in press; Reid
et al., 1992. The only long-term, though relatively small (30 pa-
tients in each group), randomized study comparing surgical
closed, open, or percutaneous commissurotomy, has been re-
ported by Farahat et al. (1998) in young population with pli-
able, noncalciﬁed valves. The 7-year results were better for
open and percutaneous procedures than for closed commissur-
otomy as assessed by a higher event-free survival (93%, 90%,
and 50%, respectively), better follow-up MVA (1.8, 1.8, and
1.3 cm2) and lower restenosis rate (6%, 6%, and 37%). In
long-term surgical series (John et al., 1983; Commerford
et al., 1982; Rihal et al., 1992). Hickey et al. (1991) reportedoup A (children and adolescent) and group B (adults). Numbers at
llow-up.
Mitral balloon valvuloplasty 131on 103 patients with closed commissurotomy (mean age
38 years) event-free rate from mitral valve replacement of
78% at 10 years and 47% at 20 years. (Rihal et al., 1992) re-
ported on 267 patients (mean age 43 years) event-free rate
fromMVR 57% at 10 years and 24% at 20 years. In our series,
the combined event-free rates after MBV is 88% at 10 years,
60% at 15 years, and 28% at 19 years were not worse than
those of surgical series.
4. Conclusions
Mitral balloon valvuloplasty, which is the procedure of choice
in the treatment of rheumatic mitral stenosis, has excellent
immediate and long-term results in patients with favorable mi-
tral valve morphology but those with less favorable anatomy
may still have reasonably good hemodynamic and symptom-
atic relief. This technique is associated with less morbidity
and long-term results are better than the historical reported
surgical results. The long-term outcome can be predicted from
baseline clinical and valvular characteristics. MBV is safe and
effective when treating patients with MS and severe pulmonary
hypertension, the latter condition being normalized over 6–
12 months after successful MBV. Severe TR regresses after
successful MBV in the presence of severe pulmonary hyperten-
sion. Severely impaired LV systolic function normalized after
successful MBV. The result of MBV in children is similar to
those in adults and the valve morphology is strong predictor
of good immediate and long-term results. MBV is safe and
effective during pregnancy with no untoward effect on the
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